JP2015131853A5 - - Google Patents

Download PDF

Info

Publication number
JP2015131853A5
JP2015131853A5 JP2015085594A JP2015085594A JP2015131853A5 JP 2015131853 A5 JP2015131853 A5 JP 2015131853A5 JP 2015085594 A JP2015085594 A JP 2015085594A JP 2015085594 A JP2015085594 A JP 2015085594A JP 2015131853 A5 JP2015131853 A5 JP 2015131853A5
Authority
JP
Japan
Prior art keywords
layer
tablet
tablet according
sodium
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015085594A
Other languages
English (en)
Japanese (ja)
Other versions
JP6138851B2 (ja
JP2015131853A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015131853A publication Critical patent/JP2015131853A/ja
Publication of JP2015131853A5 publication Critical patent/JP2015131853A5/ja
Application granted granted Critical
Publication of JP6138851B2 publication Critical patent/JP6138851B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015085594A 2010-11-19 2015-04-20 リルピビリンHClおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物 Active JP6138851B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
US61/415,600 2010-11-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013540085A Division JP2014500261A (ja) 2010-11-19 2011-11-18 リルピビリンHClおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物

Publications (3)

Publication Number Publication Date
JP2015131853A JP2015131853A (ja) 2015-07-23
JP2015131853A5 true JP2015131853A5 (enExample) 2016-01-07
JP6138851B2 JP6138851B2 (ja) 2017-05-31

Family

ID=45094284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013540085A Withdrawn JP2014500261A (ja) 2010-11-19 2011-11-18 リルピビリンHClおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
JP2015085594A Active JP6138851B2 (ja) 2010-11-19 2015-04-20 リルピビリンHClおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013540085A Withdrawn JP2014500261A (ja) 2010-11-19 2011-11-18 リルピビリンHClおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物

Country Status (36)

Country Link
US (1) US10857102B2 (enExample)
EP (2) EP2640362B2 (enExample)
JP (2) JP2014500261A (enExample)
KR (1) KR101923103B1 (enExample)
CN (2) CN103491948B (enExample)
AP (1) AP3816A (enExample)
AR (2) AR084500A1 (enExample)
AU (3) AU2011329642B2 (enExample)
BR (1) BR112013012245B1 (enExample)
CA (1) CA2818097C (enExample)
CL (1) CL2013001402A1 (enExample)
CO (1) CO6761300A2 (enExample)
CR (1) CR20130293A (enExample)
DK (1) DK2640362T4 (enExample)
EA (2) EA201691695A1 (enExample)
EC (2) ECSP13012700A (enExample)
ES (1) ES2524408T5 (enExample)
HK (1) HK1206592A1 (enExample)
HR (1) HRP20140946T1 (enExample)
IL (1) IL226300B (enExample)
MA (1) MA34735B1 (enExample)
ME (1) ME01980B (enExample)
MX (1) MX347512B (enExample)
MY (1) MY185604A (enExample)
NZ (1) NZ610729A (enExample)
PE (3) PE20211657A1 (enExample)
PH (1) PH12013501002A1 (enExample)
PL (1) PL2640362T5 (enExample)
PT (1) PT2640362E (enExample)
RS (1) RS53691B1 (enExample)
SG (3) SG190333A1 (enExample)
SM (1) SMT201400150B (enExample)
TW (1) TWI556840B (enExample)
UA (1) UA114075C2 (enExample)
WO (1) WO2012068535A1 (enExample)
ZA (1) ZA201304481B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PE20181207A1 (es) * 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
EP3645003A4 (en) * 2017-06-30 2021-03-10 VIIV Healthcare Company COMBINATION AND USES AND TREATMENTS THEREOF
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN101309675A (zh) 2005-10-14 2008-11-19 微量技术有限公司 口服剂量组合的药品包装
US20080317852A1 (en) 2005-12-14 2008-12-25 Amar Lulla Pharmaceutical Combination
BRPI0807581A2 (pt) * 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
SG173544A1 (en) 2009-02-06 2011-09-29 Gilead Sciences Inc Tablets for combination therapy
BR122021021135B1 (pt) 2009-09-21 2022-08-30 Gilead Sciences, Inc Compostos análogos de 2-flúor substituído carba-nucleosídeo, composição farmacêutica e uso dos compostos análogos de 2´-flúoro substituído carbonucleosídeo
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Similar Documents

Publication Publication Date Title
JP2015131853A5 (enExample)
HRP20140946T1 (hr) Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat
JP2017057230A5 (enExample)
JP5509086B2 (ja) フィルムコーティング割線錠剤
JP2018162255A5 (enExample)
JP2017222705A5 (enExample)
JP2016518452A5 (enExample)
JP2015038149A5 (enExample)
JP2017528507A5 (enExample)
NZ729172A (en) Combination formulation of two antiviral compounds
JP2016163571A5 (enExample)
FI3265084T3 (fi) Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
JP2011509295A5 (enExample)
JP2006516570A5 (enExample)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2019517542A5 (enExample)
JP2017506624A5 (enExample)
JP2015501808A5 (enExample)
UA117506C2 (uk) Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти
JP2020511419A5 (enExample)
JP2018535991A (ja) ドラビリン、テノホビルジソプロキシルフマル酸塩およびラミブジンを含有する医薬組成物
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
RU2019140298A (ru) Комбинация, ее применение и способы лечения с использованием указанной комбинации
JP2019533672A5 (enExample)
JP2018530566A5 (enExample)